The one-time gene therapy treatment is priced at $2.1 million and is designed to treat spinal muscular atrophy in infants.
Novartis said about 200 patients have been treated with Zolgensma since it launched last June, according to STAT.
The drug is covered for 97 percent of patients with commercial plans; 50 percent of Medicaid patients are covered.
Read the full article here.
More articles on pharmacy:
Drug shortages update: 5 things to know
Grocery store pharmacies across the country finding it harder to stay in business
AbbVie to donate $1M of drug China says will combat coronavirus
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.